Although mice fully deficient in HGSNAT represent the most severe phenotype of MPSIIIC disease, any evidence of therapeutic efficacy demonstrated in this model would be encouraging for clinical translation to human individuals with a broader clinical spectrum. Here, HGSNAT is linked to mucopolysaccharidosis type 3C.